Accessibility StatementSkip Navigation – Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelcaand atezolizumab (Tecentriq) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex, Xywavand the launch of Modeyso – DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial g ...